We’re pleased to welcome Dr. Robert Carl Meisner, MD, founding Medical Director of the McLean Ketamine Service at McLean Hospital and attending psychiatrist, Acute Psychiatric Service at Massachusetts General Hospital. Dr. Meisner will be presenting “The New Psychiatry: Promise and Peril in Psychedelics, Ketamine, and Emerging Therapies” at our NE Conference on October 8th and 9th. Don’t miss this opportunity to hear him speak live—learn more about our speakers and register today: www.alcanewengland.org/alca-ne-conference
SPEAKER: Dr. Robert Carl Meisner, MD
Title: The New Psychiatry: Promise and Peril in Psychedelics, Ketamine, and Emerging Therapies
Bio: Dr. Meisner focuses on developing novel pharmacologic interventions and ensuring safe practices for emerging neurotherapeutics. A graduate of Princeton University and Harvard Medical School, he has held academic appointments at Harvard and consulted on neuroscience leadership for hospitals, government bodies, and industry nationwide. Dr. Meisner lectures widely on interventional neurotherapeutics and novel agents, with an emphasis on disseminating evidence-based information. His team is preparing the largest naturalistic efficacy comparison of ketamine vs. esketamine in depression patients. He currently serves as Co-Chair for the National Network of Depression Centers (NNDC) Ketamine Task Force, with previous board roles at Harvard and Mangata, Inc. (pro bono). @https://lnkd.in/eGwAPexM
#ALCA #ALCANE #Speaker #Conference #Aging #InnovativeAging #AlternativeCareOptions
0 CommentsComment on Facebook